Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer

Exploding interest in immunometabolism as a source of new cancer therapeutics has been driven in large part by studies of tryptophan catabolism mediated by IDO/TDO enzymes. A chief focus in the field is IDO1, a pro-inflammatory modifier that is widely overexpressed in cancers where it blunts immunos...

Descripción completa

Detalles Bibliográficos
Autores principales: Fox, Eric, Oliver, Thomas, Rowe, Melissa, Thomas, Sunil, Zakharia, Yousef, Gilman, Paul B., Muller, Alexander J., Prendergast, George C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141803/
https://www.ncbi.nlm.nih.gov/pubmed/30254983
http://dx.doi.org/10.3389/fonc.2018.00370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141803/
https://www.ncbi.nlm.nih.gov/pubmed/30254983
http://dx.doi.org/10.3389/fonc.2018.00370

Ejemplares similares